The pharmaceutical supply chain | GDS Publishing

The Magazine

Current Issue

You could argue that anything done in a new way, however small, can be counted as an innovation. Introducing innovation at a game-changing level, however, is not so simple, and it's only going to get harder for the pharmaceutical industry.

- Issue 18
  Feb 2010
- Issue 17
  Sep 2009
- Issue 16
  Jun 2009
- Issue 15
  Feb 2009
- Issue 14
  Oct 2008
- Issue 13
  Jul 2008
- Issue 12
  Mar 2008
- Issue 11
  Dec 2007
- Issue 10
  Oct 2007
- Issue 9
  Jul 2007
- Issue 8
  Apr 2007
- Issue 7
  Jan 2007
- Issue 6
  Dec 2006
- Issue 5
  Oct 2006
- Issue 4
  Mar 2006
- Issue 3
  Mar 2006
- Issue 2
  Mar 2006
- Issue 1
  Mar 2006

Blog

Where our team of guest writers discuss what they think about the current NGP US Issues.

Peter Duncan
Director of Business Development

Can digital pathology save drug development?

Peter Duncan of Definiens discusses the potential of digital pathology.
07 Jul 2010

Comments (Total 1 Comments)

David K
Posted: 27 November 2009 @ 06:50

Modern supply chains are vulnerable to risks.
These risks should be managed before they harm the organization.
Minet Technologies offers a unique risk management workshop that can reduce the cost and improve the efficiency of the supply chain.

http://snipr.com/tfjzl

Disclaimer: All comments posted in a personal capacity

Source: www.ngpharma.com
© 2010 GDS Publishing Ltd. All rights reserved.